SCYNEXIS
SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. The last earnings update was 72 days ago. More info.
Add to Portfolio Compare Print
- SCYNEXIS has significant price volatility in the past 3 months.
SCYX Share Price and Events
7 Day Returns
1 Year Returns
SCYX Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| SCYNEXIS (SCYX) | -5.4% | 78.4% | -28.8% | -60.5% | -84.8% | - |
| US Pharmaceuticals | -0% | 4.3% | -2.1% | -0.8% | 8.3% | 22.7% |
| US Market | 0.7% | 10.2% | -1% | -8.1% | 38.8% | 38.9% |
1 Year Return vs Industry and Market
- SCYX underperformed the Pharmaceuticals industry which returned -0.8% over the past year.
- SCYX underperformed the Market in United States of America which returned -8.1% over the past year.
SCYX Value
Is SCYNEXIS undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for SCYNEXIS. This is due to cash flow or dividend data being unavailable. The share price is $0.726.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for SCYNEXIS's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
SCYNEXIS's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-09-30) in USD | $-0.56 |
| NasdaqGM:SCYX Share Price ** | NasdaqGM (2019-01-23) in USD | $0.73 |
| United States of America Pharmaceuticals Industry PE Ratio | Median Figure of 27 Publicly-Listed Pharmaceuticals Companies | 19.24x |
| United States of America Market PE Ratio | Median Figure of 3,026 Publicly-Listed Companies | 16.96x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of SCYNEXIS.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = NasdaqGM:SCYX Share Price ÷ EPS (both in USD) = 0.73 ÷ -0.56 |
-1.29x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- SCYNEXIS is loss making, we can't compare its value to the US Pharmaceuticals industry average.
- SCYNEXIS is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does
SCYNEXIS's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -1.29x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts |
22.4%per year |
| United States of America Pharmaceuticals Industry PEG Ratio | Median Figure of 22 Publicly-Listed Pharmaceuticals Companies | 1.11x |
| United States of America Market PEG Ratio | Median Figure of 2,109 Publicly-Listed Companies | 1.26x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for SCYNEXIS, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
SCYNEXIS's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-09-30) in USD | $0.59 |
| NasdaqGM:SCYX Share Price * | NasdaqGM (2019-01-23) in USD | $0.73 |
| United States of America Pharmaceuticals Industry PB Ratio | Median Figure of 171 Publicly-Listed Pharmaceuticals Companies | 2.54x |
| United States of America Market PB Ratio | Median Figure of 5,102 Publicly-Listed Companies | 1.75x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = NasdaqGM:SCYX Share Price ÷ Book Value per Share (both in USD) = 0.73 ÷ 0.59 |
1.23x |
* Primary Listing of SCYNEXIS.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- SCYNEXIS is good value based on assets compared to the US Pharmaceuticals industry average.
Value checks
We assess SCYNEXIS's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check) SCYNEXIS has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
SCYX Future Performance
How is SCYNEXIS expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- SCYNEXIS's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
- SCYNEXIS's earnings growth is expected to exceed the United States of America market average.
- SCYNEXIS's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| NasdaqGM:SCYX Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts | 22.4% |
| NasdaqGM:SCYX Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts | 75.8% |
| United States of America Pharmaceuticals Industry Earnings Growth Rate | Market Cap Weighted Average | 20.1% |
| United States of America Pharmaceuticals Industry Revenue Growth Rate | Market Cap Weighted Average | 5.3% |
| United States of America Market Earnings Growth Rate | Market Cap Weighted Average | 13.6% |
| United States of America Market Revenue Growth Rate | Market Cap Weighted Average | 7.2% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 135 | 31 | 6 | |
| 2022-12-31 | 67 | -19 | 6 | |
| 2021-12-31 | 22 | -55 | 6 | |
| 2020-12-31 | 5 | -37 | 7 | |
| 2019-12-31 | 0 | -40 | 7 | |
| 2018-12-31 | 0 | -22 | 6 |
| Date (Data in USD Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-09-30 | 0 | -27 | -22 |
| 2018-06-30 | 0 | -27 | -31 |
| 2018-03-31 | 0 | -26 | -24 |
| 2017-12-31 | 0 | -25 | -25 |
| 2017-09-30 | 0 | -24 | -21 |
| 2017-06-30 | 0 | -26 | -24 |
| 2017-03-31 | 0 | -27 | -28 |
| 2016-12-31 | 0 | -29 | -30 |
| 2016-09-30 | 0 | -31 | -35 |
| 2016-06-30 | 0 | -30 | -31 |
| 2016-03-31 | 0 | -29 | -30 |
| 2015-12-31 | 0 | -25 | -28 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
All data from SCYNEXIS Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 0.73 | 1.82 | 0.09 | 4.00 |
| 2022-12-31 | -0.20 | -0.15 | -0.24 | 3.00 |
| 2021-12-31 | -0.48 | -0.36 | -0.63 | 3.00 |
| 2020-12-31 | -0.64 | -0.34 | -0.93 | 5.00 |
| 2019-12-31 | -0.69 | -0.56 | -0.87 | 6.00 |
| 2018-12-31 | -0.51 | -0.49 | -0.55 | 3.00 |
| Date (Data in USD Millions) | EPS * |
|---|---|
| 2018-09-30 | -0.56 |
| 2018-06-30 | -0.90 |
| 2018-03-31 | -0.84 |
| 2017-12-31 | -0.94 |
| 2017-09-30 | -0.82 |
| 2017-06-30 | -0.96 |
| 2017-03-31 | -1.26 |
| 2016-12-31 | -1.58 |
| 2016-09-30 | -2.12 |
| 2016-06-30 | -2.22 |
| 2016-03-31 | -2.19 |
| 2015-12-31 | -2.33 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if SCYNEXIS will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess SCYNEXIS's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
SCYNEXIS has a total score of 5/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
SCYX Past Performance
How has SCYNEXIS performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- SCYNEXIS does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
- Unable to compare SCYNEXIS's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare SCYNEXIS's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
All data from SCYNEXIS Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in USD Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-09-30 | 0.26 | -22.00 | 8.35 | 20.26 |
| 2018-06-30 | 0.26 | -30.75 | 7.93 | 20.78 |
| 2018-03-31 | 0.26 | -24.19 | 8.16 | 19.63 |
| 2017-12-31 | 0.26 | -25.06 | 8.25 | 18.33 |
| 2017-09-30 | 0.26 | -20.92 | 8.14 | 16.71 |
| 2017-06-30 | 0.26 | -23.75 | 8.01 | 17.14 |
| 2017-03-31 | 0.26 | -27.67 | 7.33 | 19.35 |
| 2016-12-31 | 0.26 | -29.99 | 7.80 | 20.08 |
| 2016-09-30 | 0.26 | -34.93 | 8.62 | 22.21 |
| 2016-06-30 | 0.26 | -31.23 | 10.89 | 20.77 |
| 2016-03-31 | 0.26 | -29.59 | 12.49 | 17.40 |
| 2015-12-31 | 0.26 | -28.34 | 12.17 | 16.44 |
| 2015-09-30 | 1.26 | -23.33 | 11.66 | 13.19 |
| 2015-06-30 | 1.26 | -19.13 | 9.64 | 12.21 |
| 2015-03-31 | 1.26 | -11.23 | 8.62 | 10.75 |
| 2014-12-31 | 1.26 | -7.24 | 7.62 | 8.29 |
| 2014-09-30 | 3.87 | -41.94 | 6.81 | 6.78 |
| 2014-06-30 | 7.97 | -42.57 | 5.83 | 5.35 |
| 2014-03-31 | 12.13 | -46.68 | 4.50 | 4.53 |
| 2013-12-31 | 16.86 | -46.81 | 4.38 | 4.36 |
| 2012-12-31 | 16.84 | -11.48 | 4.74 | 8.93 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if SCYNEXIS has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if SCYNEXIS has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if SCYNEXIS improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess SCYNEXIS's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
SCYNEXIS has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
SCYX Health
How is SCYNEXIS's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up SCYNEXIS's finances.
The net worth of a company is the difference between its assets and liabilities.
- SCYNEXIS is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- SCYNEXIS's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 3.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from SCYNEXIS Company Filings, last reported 3 months ago.
| Date (Data in USD Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-09-30 | 27.88 | 14.97 | 49.49 |
| 2018-06-30 | 26.55 | 14.86 | 55.19 |
| 2018-03-31 | 36.84 | 14.76 | 63.70 |
| 2017-12-31 | 21.41 | 14.65 | 43.89 |
| 2017-09-30 | 27.26 | 14.55 | 47.71 |
| 2017-06-30 | 31.66 | 14.45 | 49.34 |
| 2017-03-31 | 33.53 | 14.35 | 54.90 |
| 2016-12-31 | 34.82 | 14.25 | 58.59 |
| 2016-09-30 | 33.18 | 14.17 | 52.35 |
| 2016-06-30 | 43.88 | 0.00 | 50.34 |
| 2016-03-31 | 35.04 | 0.00 | 38.02 |
| 2015-12-31 | 41.95 | 0.00 | 46.99 |
| 2015-09-30 | 49.97 | 0.00 | 53.77 |
| 2015-06-30 | 56.77 | 0.00 | 57.06 |
| 2015-03-31 | 27.44 | 0.00 | 27.62 |
| 2014-12-31 | 33.43 | 0.00 | 32.24 |
| 2014-09-30 | 36.14 | 0.00 | 34.04 |
| 2014-06-30 | 39.42 | 0.00 | 38.43 |
| 2014-03-31 | -20.43 | 15.00 | 0.65 |
| 2013-12-31 | -20.92 | 15.00 | 1.40 |
| 2012-12-31 | -19.17 | 26.44 | 2.39 |
- SCYNEXIS's level of debt (53.7%) compared to net worth is high (greater than 40%).
- SCYNEXIS had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- SCYNEXIS has sufficient cash runway for 2.9 years based on current free cash flow.
- SCYNEXIS has sufficient cash runway for 2.8 years if free cash flow continues to grow at historical rates of 5.5% each year.
Financial health checks
We assess SCYNEXIS's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) SCYNEXIS has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
SCYX Dividends
What is SCYNEXIS's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
$2,000 of
SCYNEXIS
shares you are expected to receive
$0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate SCYNEXIS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate SCYNEXIS's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 7 Analyst Estimates (S&P Global) | See Below |
| United States of America Pharmaceuticals Industry Average Dividend Yield | Market Cap Weighted Average of 11 Stocks | 2.7% |
| United States of America Market Average Dividend Yield | Market Cap Weighted Average of 1986 Stocks | 2.6% |
| United States of America Minimum Threshold Dividend Yield | 10th Percentile | 0.9% |
| United States of America Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| United States of America Top 25% Dividend Yield | 75th Percentile | 3.7% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in $) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 | ||
| 2018-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as SCYNEXIS has not reported any payouts.
- Unable to verify if SCYNEXIS's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess SCYNEXIS's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can SCYNEXIS afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) SCYNEXIS has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
SCYX Management
CEO
| COMPENSATION | $1,220,648 |
| AGE | 58 |
| TENURE AS CEO | 3.8 years |
CEO Bio
Dr. Marco Taglietti, M.D. has been the Chief Executive Officer of SCYNEXIS, Inc. since April 1, 2015 and has been President since September 24, 2015. Dr. Taglietti served as Senior Vice President, Head of Global Research and Development, at Stiefel Laboratories, Inc for three years. He served as the Chief Medical Officer and Executive Vice President of Drug Development & Research at Forest Laboratories Inc. since December 2013. He served as the President of the Forest Research Institute (FRI) of Forest Laboratories Inc. from December 2010 to December 2013. He served as Senior Vice President of Research & Development at Forest Laboratories Inc. from December 2010 to December 2013. He served as an Executive Vice President of Research and Development and Chief Medical Officer of Forest Laboratories. Dr. Taglietti joined Forest in August 2007 as an Executive Vice President of Development and Chief Medical Officer of wholly-owned subsidiary Forest Research Institute, Inc. He served as Vice President of Research & Development of Forest Laboratories Inc. since December 2008. He joined Stiefel after 12 years at Schering-Plough Corporation where he last held the position of Vice President of Worldwide Clinical Research at Anti-Infectives, Oncology, CNS, Endocrinology and Dermatology. Dr. Taglietti began his career at Marion Merrell Dow Research Institute. He also served as President of the Forest Research Institute. He has been a Director of Delcath Systems, Inc. since December 11, 2014 and SCYNEXIS, Inc. since November 2014. He has been a Trustee of BioNJ Inc. since February 25, 2016. Dr. Taglietti serves as Director of TransCelerate BioPharma Inc. He served as an Independent Director of NephroGenex, Inc. since October 1, 2014 until March 6, 2017. He received his medical degree and board certifications from the University of Pavia in Italy.
CEO Compensation
- Marco's compensation has increased whilst company is loss making.
- Marco's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure
Average tenure and age of the SCYNEXIS management team in years:
- The tenure for the SCYNEXIS management team is about average.
Management Team
Marco Taglietti
CEO, President & Director
$1M
58
3.8 yrs
Eric Francois
Chief Financial Officer
$646K
43
3.2 yrs
David Angulo
Chief Medical Officer
$768K
53
3.6 yrs
Scott Sukenick
General Counsel & Corporate Secretary
40
1.2 yrs
Board of Directors Tenure
Average tenure and age of the SCYNEXIS board of directors in years:
- The tenure for the SCYNEXIS board of directors is about average.
Board of Directors
Guy MacDonald
Chairman of the Board
$75K
59
3.6 yrs
Marco Taglietti
CEO, President & Director
$1M
58
4.2 yrs
Ann Hanham
Independent Director
$74K
65
10.1 yrs
Pat Machado
Independent Director
$74K
54
3.3 yrs
Dave Hastings
Independent Director
$73K
57
3.3 yrs
Steve Gilman
Independent Director
$68K
65
3.9 yrs
Who owns this company?
Recent Insider Trading
- More shares have been bought than sold by SCYNEXIS insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price ($) | Value ($) | |
|---|---|---|---|---|---|---|---|---|---|---|
| 14. Jan 19 | Buy | Marco Taglietti | Individual | 10. Jan 19 | 10. Jan 19 | 25,000 | $0.69 | $17,250 | ||
| 02. Jan 19 | Buy | Marco Taglietti | Individual | 31. Dec 18 | 31. Dec 18 | 25,000 | $0.46 | $11,500 | ||
| 02. Jan 19 | Buy | David Angulo | Individual | 31. Dec 18 | 31. Dec 18 | 12,000 | $0.50 | $5,951 | ||
| 10. Sep 18 | Buy | David Angulo | Individual | 06. Sep 18 | 06. Sep 18 | 7,000 | $1.27 | $8,890 | ||
| 27. Aug 18 | Buy | Marco Taglietti | Individual | 23. Aug 18 | 23. Aug 18 | 25,000 | $1.29 | $32,250 | ||
| 02. Apr 18 | Buy | David Angulo | Individual | 29. Mar 18 | 29. Mar 18 | 6,000 | $1.36 | $8,160 | ||
| 12. Mar 18 | Buy | Marco Taglietti | Individual | 08. Mar 18 | 08. Mar 18 | 100,000 | $1.69 | $169,000 | ||
| 12. Mar 18 | Buy | Eric Francois | Individual | 08. Mar 18 | 08. Mar 18 | 5,917 | $1.69 | $10,000 | ||
| 12. Mar 18 | Buy | David Angulo | Individual | 08. Mar 18 | 08. Mar 18 | 14,790 | $1.69 | $24,995 | ||
| 12. Mar 18 | Buy | David Angulo | Individual | 08. Mar 18 | 08. Mar 18 | 7,000 | $1.39 | $9,730 | ||
| 12. Mar 18 | Buy | David Hastings | Individual | 08. Mar 18 | 08. Mar 18 | 11,834 | $1.69 | $19,999 | ||
| 12. Mar 18 | Buy | Scott Sukenick | Individual | 08. Mar 18 | 08. Mar 18 | 2,959 | $1.69 | $5,001 | ||
Management checks
We assess SCYNEXIS's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) SCYNEXIS has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
SCYX News
Simply Wall St News
Could SCYNEXIS, Inc.'s (NASDAQ:SCYX) Investor Composition Influence The Stock Price?
We also tend to see lower insider ownership in companies that were previously publicly owned. … SCYNEXIS is a smaller company with a market capitalization of US$29m, so it may still be flying under the radar of many institutional investors. … We can zoom in on the different ownership groups, to learn more about SCYX
Simply Wall St - – Full articleHow Much Are SCYNEXIS, Inc. (NASDAQ:SCYX) Insiders Spending On Buying Shares?
So shareholders might well want to know whether insiders have been buying or selling shares in SCYNEXIS, Inc. … It's very possible they regret the purchase, but it's more likely they are bullish about the company. … In the last twelve months there was more buying than selling by SCYNEXIS insiders
Simply Wall St - – Full articleWhat Investors Should Know About SCYNEXIS Inc's (NASDAQ:SCYX) Financial Strength
SCYNEXIS Inc (NASDAQ:SCYX) is a small-cap stock with a market capitalization of US$42m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … So, understanding the company's financial health becomes
Simply Wall St - – Full articleIs SCYNEXIS Inc (NASDAQ:SCYX) A Financially Sound Company?
Investors are always looking for growth in small-cap stocks like SCYNEXIS Inc (NASDAQ:SCYX), with a market cap of US$75.42m. … However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is
Simply Wall St - – Full articleSCYNEXIS Inc's (NASDAQ:SCYX) Path To Profitability
SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. … The US$80.10m market-cap posted a loss in its most recent financial year of -US$25.06m and a latest trailing-twelve-month loss of -US$24.19m shrinking the gap between loss and breakeven. … View out our latest analysis for SCYNEXIS
Simply Wall St - – Full articleDid SCYNEXIS Inc's (NASDAQ:SCYX) Earnings Growth Outperform The Industry?
When SCYNEXIS Inc (NASDAQ:SCYX) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peers on average. … View our latest analysis for SCYNEXIS Were SCYX's earnings stronger than its past performances and the industry? … I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data.
Simply Wall St - – Full articleSCYX Company Info
Map
Description
SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collaborations with Merck Sharp & Dohme Corp. and R-Pharm, CJSC, to develop and commercialize rights for SCY-078. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Jersey City, New Jersey.
Details
| Name: | SCYNEXIS, Inc. |
| SCYX | |
| Exchange: | NasdaqGM |
| Founded: | 1999 |
| $36,458,471 | |
| 47,971,673 | |
| Website: | http://www.scynexis.com |
| Address: |
SCYNEXIS, Inc. 101 Hudson Street, Suite 3610, Jersey City, New Jersey, 07302, United States |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| NasdaqGM | SCYX | Common Stock | Nasdaq Global Market | US | USD | 02. May 2014 | |
| DB | 135 | Common Stock | Deutsche Boerse AG | DE | EUR | 02. May 2014 | |
| LSE | 0L49 | Common Stock | London Stock Exchange | GB | USD | 02. May 2014 |
Number of employees
Current staff
Industry
| Pharmaceuticals | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/01/24 00:31 |
| End of day share price update: | 2019/01/23 00:00 |
| Last estimates confirmation: | 2019/01/04 |
| Last earnings filing: | 2018/11/13 |
| Last earnings reported: | 2018/09/30 |
| Last annual earnings reported: | 2017/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
